FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009673463> ?p ?o ?g. }

• W2009673463 endingPage "1586" @default.
• W2009673463 startingPage "1586" @default.
• W2009673463 abstract "The Authors Reply—Dr. Kohlwes correctly points out that, in the treatment of hypertension, chlorthalidone is the thiazide diuretic for which we have the best evidence. Many clinicians have made a conceptual leap by assuming that hydrochlorothiazide (HCTZ) confers similar reductions in stroke, myocardial infarction, and total cardiovascular events. While intuitively plausible, this is not supported by the literature. No trials have directly compared the cardiovascular risk reduction of the two diuretics head-to-head. However, in a recent meta-analysis of nine randomized trials that included a diuretic as one arm, fewer cardiovascular events occurred among patients receiving chlorthalidone than among those who received HCTZ.1 In addition, in the MRFIT trial, fewer cardiovascular events occurred for patients taking chlorthalidone than for those taking HCTZ2; however, the choice of diuretic was not randomly assigned. An important difference that may account for these observations is the longer half-life of chlorthalidone, which confers better reduction in nighttime blood pressure than HCTZ.3 These data provide another example of the observation that all drugs that lower blood pressure do not equally reduce cardiovascular risk.4Several practical barriers exist. Chlorthalidone is approximately twice as potent as HCTZ. Therefore, the starting dose should be 12.5 mg daily; however, only 25 mg and 50 mg tabs are available. Patients must split the pills. Not all retail pharmacies routinely stock chlorthalidone. Combination antihypertensive medications simplify treatment regimens and improve adherence. However, at present, the only combination antihypertensive medications that include chlorthalidone are those with a beta blocker, clonidine, or an angiotensin receptor blocker. None of these are optimal first-line dual therapies for the treatment of hypertension.4 No combination medications exist that include ACE inhibitors or calcium channel blockers. In addition, chlorthalidone probably causes more hypokalemia than HCTZ; it is particularly important to measure serum electrolytes 2–3 weeks after starting the drug.Once clinicians begin to prescribe chlorthalidone more often, we should expect the pharmaceutical industry to respond with lower dose tablets and more combination pills to improve adherence. For new starts, clinicians should prescribe chlorthalidone when a diuretic is indicated for the treatment of hypertension. For patients who have been stable on HCTZ, we should discuss the more robust evidence supporting chlorthalidone with our patients, and consider changing HCTZ to chlorthalidone." @default.
• W2009673463 created "2016-06-24" @default.
• W2009673463 creator A5040102724 @default.
• W2009673463 date "2012-09-11" @default.
• W2009673463 modified "2023-09-25" @default.
• W2009673463 title "ACE Inhibitors Versus ARBs Versus DRIs: A Systematic Update" @default.
• W2009673463 cites W2008895422 @default.
• W2009673463 cites W2111844910 @default.
• W2009673463 cites W2129922429 @default.
• W2009673463 cites W2153152935 @default.
• W2009673463 doi "https://doi.org/10.1007/s11606-012-2213-3" @default.
• W2009673463 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3509301" @default.
• W2009673463 hasPublicationYear "2012" @default.
• W2009673463 type Work @default.
• W2009673463 sameAs 2009673463 @default.
• W2009673463 citedByCount "0" @default.
• W2009673463 crossrefType "journal-article" @default.
• W2009673463 hasAuthorship W2009673463A5040102724 @default.
• W2009673463 hasBestOaLocation W20096734631 @default.
• W2009673463 hasConcept C126322002 @default.
• W2009673463 hasConcept C17744445 @default.
• W2009673463 hasConcept C189708586 @default.
• W2009673463 hasConcept C199539241 @default.
• W2009673463 hasConcept C2779473830 @default.
• W2009673463 hasConcept C71924100 @default.
• W2009673463 hasConceptScore W2009673463C126322002 @default.
• W2009673463 hasConceptScore W2009673463C17744445 @default.
• W2009673463 hasConceptScore W2009673463C189708586 @default.
• W2009673463 hasConceptScore W2009673463C199539241 @default.
• W2009673463 hasConceptScore W2009673463C2779473830 @default.
• W2009673463 hasConceptScore W2009673463C71924100 @default.
• W2009673463 hasIssue "12" @default.
• W2009673463 hasLocation W20096734631 @default.
• W2009673463 hasLocation W20096734632 @default.
• W2009673463 hasLocation W20096734633 @default.
• W2009673463 hasOpenAccess W2009673463 @default.
• W2009673463 hasPrimaryLocation W20096734631 @default.
• W2009673463 hasRelatedWork W2011588493 @default.
• W2009673463 hasRelatedWork W2082647424 @default.
• W2009673463 hasRelatedWork W2115099528 @default.
• W2009673463 hasRelatedWork W2284198476 @default.
• W2009673463 hasRelatedWork W2581110579 @default.
• W2009673463 hasRelatedWork W2906204823 @default.
• W2009673463 hasRelatedWork W3029969037 @default.
• W2009673463 hasRelatedWork W4230570618 @default.
• W2009673463 hasRelatedWork W4239204192 @default.
• W2009673463 hasRelatedWork W4249380099 @default.
• W2009673463 hasVolume "27" @default.
• W2009673463 isParatext "false" @default.
• W2009673463 isRetracted "false" @default.
• W2009673463 magId "2009673463" @default.
• W2009673463 workType "article" @default.